EMA confirms recommendations to minimise risk of brain infection PML with Tysabri

View source ↗

Summary

EMA confirms recommendations to minimize the risk of progressive multifocal leukoencephalopathy (PML) with Tysabri (natalizumab).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)